MEN1 intragenic deletions may represent the most prevalent somatic event in sporadic primary hyperparathyroidism

European Journal of Endocrinology

Volumn 168, Issue 2, 2013, Pages 119-128

  Alvelos, Maria Inês ^a   Vinagre, João ^a,b   Fonseca, Elsa ^a,b,c   Barbosa, Eva ^a,d   Teixeira Gomes, José ^a   Sobrinho Simões, Manuel ^a,b,c   Soares, Paula ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

^d HOSPITAL PEDRO HISPANO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA; KI 67 ANTIGEN; METHIONINE; PARAFIBROMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CDKN1B GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CTNNB1 GENE; FEMALE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; MALE; MOLECULAR TYPING; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 GENE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PARATHYROID TUMOR; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RET GENE; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENE DELETION; HUMANS; HYPERPARATHYROIDISM; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MUTATION; PARATHYROID NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RETROSPECTIVE STUDIES;

EID: 84872335935     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0327     Document Type: Article

References (54)

1. Nilsson IL, Yin L, Lundgren E, Rastad J & Ekbom A. Clinical presentation of primary hyperparathyroidism in Europe - nationwide cohort analysis on mortality from nonmalignant causes. Journal of Bone and Mineral Research 2002 17 (Suppl 2) N68-N74. (Pubitemid 35222315)
2. Carlson D. Parathyroid pathology: hyperparathyroidism and parathyroid tumors. Archives of Pathology & Laboratory Medicine 2010 134 1639-1644.
3. Scarpelli D, D'Aloiso L, Arturi F, Scillitani A, Presta I, Bisceglia M, Cristofaro C, Russo D & Filetti S. Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics. Journal of Endocrinological Investigation 2004 27 1015-1021.
4. Dinnen JS, Greenwoood RH, Jones JH, Walker DA & Williams ED. Parathyroid carcinoma in familial hyperparathyroidism. Journal of Clinical Pathology 1977 30 966-975. (doi:10.1136/jcp.30.10.966)
5. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J & Atkinson MJ. Germ-line mutations in p27kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. PNAS 2006 103 15558-15563. (doi:10.1073/pnas.0603877103)
6. Marinoni I & Pellegata NS. p27kip1: a new multiple endocrine neoplasia gene? Neuroendocrinology 2011 93 19-28. (doi:10.1159/000320366)
7. Georgitsi M. MEN-4 and othermultiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) mutations. Best Practice & Research. Clinical Endocrinology & Metabolism 2010 24 425-437. (doi:10.1016/j.beem.2010.01.001)
8. Malanga D, De Gisi S, Riccardi M, Scrima M, De Marco C, Robledo M & Viglietto G. Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype. European Journal of Endocrinology 2012 166 551-560. (doi:10.1530/EJE-11-0929)
9. Tahara H, Smith AP, Gaz RD & Arnold A. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism 1996 81 3663-3667. (doi:10.1210/jc.81.10.3663)
10. Kishikawa S, Shan L, Ogihara K, Utsunomiya H, Nakamura M, Nakamura Y, Naito A & Kakudo K. Overexpression and genetic abnormality of p53 in parathyroid adenomas. Pathology International 1999 49 853-857. (doi:10.1046/j.1440-1827.1999.00961.x)
11. Giles RH, van Es JH & Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochimica et Biophysica Acta 2003 1653 1-24. (doi:10.1016/S0304-419X(03)00005-2)
12. Polakis P. Wnt signaling and cancer. Genes and Development 2000 14 1837-1851. (doi:10.1101/gad.14.15.1837)
13. Bjorklund P, Akerstrom G & Westin G. Accumulation of nonphosphorylated β-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors. Journal of Clinical Endocrinology and Metabolism 2007 92 338-344. (doi:10.1210/jc.2006-1197)
14. Ikeda S, Ishizaki Y, Shimizu Y, Fujimori M, Ojima Y, Okajima M, Sugino K & Asahara T. Immunohistochemistry of cyclin D1 and β-catenin, and mutational analysis of exon 3 of β-catenin gene in parathyroid adenomas. International Journal of Oncology 2002 20 463-466.
15. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997 276 404-407. (doi:10.1126/science.276.5311.404)
16. Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, Buisson N, De Witte K, Salandre J, Lenoir G et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Human Molecular Genetics 1997 6 1177-1183. (doi:10.1093/hmg/6.7.1177)
17. Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FS & Chandrasekharappa SC. Menin, the product of the MEN1 gene, is a nuclear protein. PNAS 1998 95 1630-1634. (doi:10.1073/pnas.95.4.1630)
18. Lemos MC & Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Human Mutation 2008 29 22-32. (doi:10.1002/humu.20605)
19. Heppner C, Kester MB, Agarwal SK, Debelenko LV, Emmert-Buck MR, Guru SC, Manickam P, Olufemi SE, Skarulis MC, Doppman JL et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nature Genetics 1997 16 375-378. (doi:10.1038/ng0897-375)
20. Miedlich S, Krohn K, Lamesch P, Muller A & Paschke R. Frequency of somatic MEN1 gene mutations in monoclonal parathyroid tumours of patients with primary hyperparathyroidism. European Journal of Endocrinology 2000 143 47-54. (doi:10.1530/eje.0.1430047)
21. Westin G, Bjorklund P & Akerstrom G. Molecular genetics of parathyroid disease. World Journal of Surgery 2009 33 2224-2233. (doi:10.1007/s00268-009-0022-6)
22. Arnold A, Motokura T, Bloom T, Kronenberg H, Ruderman J, Juppner H & Kim HG. The putative oncogene PRAD1 encodes a novel cyclin. Cold Spring Harbor Symposia on Quantitative Biology 1991 56 93-97. (doi:10.1101/SQB.1991.056.01. 013)
23. Fu M, Wang C, Li Z, Sakamaki T & Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004 145 5439-5447. (doi:10.1210/en.2004-0959)
24. Arnold A, Shattuck TM, Mallya SM, Krebs LJ, Costa J, Gallagher J, Wild Y & Saucier K. Molecular pathogenesis of primary hyperparathyroidism. Journal of Bone and Mineral Research 2002 17 (Suppl 2) N30-N36. (Pubitemid 35222310)
25. Mallya SM & Arnold A. Cyclin D1 in parathyroid disease. Frontiers in Bioscience 2000 5 D367-D371. (doi:10.2741/Mallya)
26. Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. Journal of Medical Genetics 2003 40 657-663. (doi:10.1136/jmg.40.9.657)
27. Miller SA, Dykes DD & Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research 1988 16 1215. (doi:10.1093/nar/16.3.1215)
28. Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira MC & Sobrinho-Simoes M. E-cadherin loss rather than β-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 2003 42 580-587. (doi:10.1046/j.1365-2559.2003.01642.x)
29. Pedrazzani C, Corso G, Velho S, Leite M, Pascale V, Bettarini F, Marrelli D, Seruca R & Roviello F. Evidence of tumor microsatellite instability in gastric cancer with familial aggregation. Familial Cancer 2009 8 215-220. (doi:10.1007/s10689-008-9231-7)
30. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. New England Journal of Medicine 2000 343 1863-1875. (doi:10.1056/NEJM200012213432508)
31. Tsukada T, Yamaguchi K & Kameya T. The MEN1 gene and associated diseases: an update. Endocrine Pathology 2001 12 259-273. (doi:10.1385/EP:12:3: 259)
32. Tham E, Grandell U, Lindgren E, Toss G, Skogseid B & Nordenskjold M. Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. Journal of Clinical Endocrinology and Metabolism 2007 92 3389-3395. (doi:10.1210/jc.2007-0476)
33. Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC, Doppman JL, Kim YS, Lubensky IA, Zhuang Z et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Human Molecular Genetics 1997 6 1169-1175. (doi:10.1093/hmg/6.7.1169)
34. Cavaco BM, Domingues R, Bacelar MC, Cardoso H, Barros L, Gomes L, Ruas MM, Agapito A, Garrao A, Pannett AA et al. Mutational analysis of Portuguese families with multiple endocrine neoplasia type 1 reveals large germline deletions. Clinical Endocrinology 2002 56 465-473. (doi:10.1046/j.1365-2265. 2002.01505.x)
35. Kassem M, Kruse TA, Wong FK, Larsson C & Teh BT. Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree. Journal of Clinical Endocrinology and Metabolism 2000 85 165-167. (doi:10.1210/jc.85.1.165)
36. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 2001 86 5658-5671. (doi:10.1210/jc.86.12.5658)
37. Peppa M, Boutati E, Kamakari S, Pikounis V, Peros G, Koutsodontis G, Metaxa-Mariatou V, Economopoulos T, Raptis SA & Hadjidakis D. Novel germline mutations of the MEN1 gene in Greek families with multiple endocrine neoplasia type 1. Clinical Endocrinology 2009 70 75-81. (doi:10.1111/j.1365-2265.2008. 03308.x)
38. Correa P, Lundgren E, Rastad J, Akerstrom G, Westin G & Carling T. Multiple endocrine neoplasia type 1 polymorphism D418D is associated with sporadic primary hyperparathyroidism. Surgery 2002 132 450-455. (doi:10.1016/S0039-6060(02)00110-1)
39. Khajavi M, Inoue K & Lupski JR. Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. European Journal of Human Genetics 2006 14 1074-1081. (doi:10.1038/sj.ejhg.5201649)
40. Newey PJ, Nesbit MA, Rimmer AJ, Attar M, Head RT, Christie PT, Gorvin CM, Stechman M, Gregory L, Mihai R et al. Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism 2012 97 E1995-E2005. (doi:10.1210/jc.2012-2303)
41. Li L, McVety S, Younan R, Liang P, Du Sart D, Gordon PH, Hutter P, Hogervorst FB, Chong G & Foulkes WD. Distinct patterns of germline deletions in MLH1 and MSH2: the implication of Alu repetitive element in the genetic etiology of Lynch syndrome (HNPCC). Human Mutation 2006 27 388. (doi:10.1002/humu.9417)
42. Agata S, Dalla Palma M, Callegaro M, Scaini MC, Menin C, Ghiotto C, Nicoletto O, Zavagno G, Chieco-Bianchi L, D'Andrea E et al. Large genomic deletions inactivate the BRCA2 gene in breast cancer families. Journal of Medical Genetics 2005 42 e64. (doi:10.1136/jmg.2005.032789)
43. Deininger PL & Batzer MA. Alu repeats and human disease. Molecular Genetics and Metabolism 1999 67 183-193. (doi:10.1006/mgme.1999.2864)
44. Fukuuchi A, Nagamura Y, Yaguchi H, Ohkura N, Obara T & Tsukada T. Awhole MEN1 gene deletion flanked by Alu repeats in a family with multiple endocrine neoplasia type 1. Japanese Journal of Clinical Oncology 2006 36 739-744. (doi:10.1093/jjco/hyl089)
45. Erlandson A, Samuelsson L, Hagberg B, Kyllerman M, Vujic M & Wahlstrom J. Multiplex ligation-dependent probe amplification (MLPA) detects large deletions in the MECP2 gene of Swedish Rett syndrome patients. Genetic Testing 2003 7 329-332. (doi:10.1089/109065703322783707)
46. Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP & Harrison CJ. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 2010 49 1104-1113. (doi:10.1002/gcc.20818)
47. Theodoropoulou M, Cavallari I, Barzon L, D'Agostino DM, Ferro T, Arzberger T, Grubler Y, Schaaf L, Losa M, Fallo F et al. Differential expression of menin in sporadic pituitary adenomas. Endocrine-Related Cancer 2004 11 333-344. (doi:10.1677/erc.0.0110333)
48. Cavallari I, Silic-Benussi M, Rende F, Martines A, Fogar P, Basso D, Vella MD, Pedrazzoli S, Herman JG, Chieco-Bianchi L et al. Decreased expression and promoter methylation of the menin tumor suppressor in pancreatic ductal adenocarcinoma. Genes, Chromosomes & Cancer 2009 48 383-396. (doi:10.1002/gcc.20650)
49. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. PNAS 1994 91 9700-9704. (doi:10.1073/pnas.91.21. 9700)
50. Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, Feurer M, Weidt E, Puranakanitstha C, Neuhaus C et al . VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Research 2000 60 1942-1948. (Pubitemid 30207656)
51. Astuti D, Morris M, Krona C, Abel F, Gentle D, Martinsson T, Kogner P, Neumann HP, Voutilainen R, Eng C et al. Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma. British Journal of Cancer 2004 91 1835-1841. (doi:10.1038/sj.bjc.6602202)
52. Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C & Dammann R. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 2006 16 633-642. (doi:10.1089/thy.2006.16. 633)
53. Gao SB, Feng ZJ, Xu B, Chen Y, Zheng HH, Yin P, Hua X & Jin GH. Menin represses malignant phenotypes of melanoma through regulating multiple pathways. Journal of Cellular and Molecular Medicine 2011 15 2353-2363. (doi:10.1111/j.1582-4934.2010.01222.x)
54. Jager AC, Friis-Hansen L, Hansen TV, Eskildsen PC, Solling K, Knigge U, Hansen CP, Andersen PH, Brixen K, Feldt-Rasmussen U et al. Characteristics of the Danish families with multiple endocrine neoplasia type 1. Molecular and Cellular Endocrinology 2006 249 123-132. (doi:10.1016/j.mce.2006.02.008)